Comparative efficacy and safety of Chinese patent medicines of iron deficiency anemia during pregnancy:A network meta-analysis

BACKGROUND Iron deficiency anemia(IDA)is a prevalent nutritional disorder during pregnancy.Clinical studies indicate that incorporating Chinese patent medicines(CPMs)with oral iron(OI)in treating IDA in pregnancy can reduce adverse effects and improve clinical outcomes.Nonetheless,the comparative efficacy of different CPMs remains unclear.AIM To assess the safety and effectiveness of different CPMs for treating IDA during pregnancy using network meta-analysis.METHODS We conducted a search for randomized controlled trials(RCTs)that combined CPM and OI for IDA treatment in pregnancy,spanning from 2013 to the present.Data analysis was performed using Rev Man 5.3 and Stata 14.0 on literature that satisfied the quality criteria.RESULTS The analysis included 45 RCTs,encompassing 4422 pregnant patients with IDA.Six CPMs were examined,including Shengxuebao Mixture,Shengxuening Tablets(SXN),Yiqi Weixue CPMs(YQWX),Jianpi Shengxue CPMs(JPSX),Yiqi Buxue Tablets,and Compound Hongyi Buxue Oral Liquid(FFHY).Findings indicated that FFHY+OI significantly improved the clinical effective rate.SXN+OI was most effective in boosting red blood cells counts and hemoglobin levels.YQWX+OI showed superior results in improving serum ferritin,and SXN+OI was most effective in increasing serum iron levels.JPSX+OI was optimal in reducing adverse pregnancy outcomes,while YQBX+OI effectively minimized adverse events.A cluster analysis suggested that SXN+OI could be the potentially optimal therapeutic regimen for IDA in pregnancy.CONCLUSION This study demonstrates that the combination of OI with CPMs offers better outcomes than OI alone.Based on clinical efficacy and other measured outcomes,SXN+OI emerges as the most effective treatment modality for improving the health of pregnant patients with IDA.

Efficacy and safety of oral Chinese patent medicine combined with sacubitril/valsartan in the treatment of chronic heart failure:A Metaanalysis

Objective:To systematically evaluate the clinical efficacy of oral Chinese patent medicine combined with sacubitril/valsartan in treating chronic heart failure(CHF).Methods:CNKI,CSPD,CCD,CBM,PubMed,Web of Science,Cochrane Library and EMbase were retrieved to screen out randomized controlled trials Chinese patent medicine and Western medicine in treating CHF.Manual retrieval was also applied as a supplement.The Cochrane Reviewers Handbook 5.1.0 was used to evaluate the bias risk of the included studies and RevMan 5.4 software was used for Meta-analysis.Results:A total of 1301 patients enrolled in the 13 RCTs were included.According to the results of Meta-analysis,a combination of oral Chinese patent medicine and sacubitril/valsartan could further improve total effectiveness rate(RR=1.23,95%CI[1.16,1.30],P<0.001),increase 6 minutes’walk distance(MD=53.04,95%CI[33.43,72.64],P<0.001),improve left ventricular ejection fraction(MD=6.67,95%CI[5.15,8.19],P<0.001)and stroke volume(MD=7.56,95%CI[3.94,11.18],P<0.001),reduce left ventricular end-diastolic dimension(MD=-3.68,95%CI[-4.57,-2.78],P<0.001)and N terminal pro B type natriuretic peptide(MD=-434.08,95%CI[-518.95,-349.22],P<0.001)and no statistically significant difference in drug safety was found between the sacubitril/valsartan-only group and the combined treatment group(RR=0.73,95%CI[0.32,1.65],P=0.45).Conclusion:It’s indicated that a combination of traditional Chinese patent medicine and sacubitril/valsartan had a good clinical efficacy in the treatment of CHF,which had certain guiding significance for clinical practice.

Clinical research progress of oral administration of traditional Chinese medicine in the treatment of dry eyes

Dry eye is a common and frequently occurring ophthalmology disease with complex etiology and easy recurrence.Oral administration of traditional Chinese medicine has the characteristicsof high curative effect and little toxic and side effect in the treatment of dry eye.This paper collates the domestic reported clinical studies on the oral administration of traditional Chinese medicine in the treatment of dry eye,which are discussed from four aspects:special prescription for specific disease,addition and subtraction of main prescription,treatment based on syndrome differentiation and proprietary Chinese medicine.The curative effect and advantages of traditional Chinese medicine in the treatment of dry eye are demonstrated,providing a reference for the treatment of dry eye in the future.

Treatment of Irritable Bowel Syndrome by Oral Administration of Chinese Medicines and Retention-Enema——A Report of 50 Cases

Irritable bowel syndrome (IBS), a common disease of intestinal dysfunction, is also called emotional enteritis, mucous enteritis, irritable colon and so on1. It is often lingering with a long disease course and is easy to recur. The author has in recent years treated 50 cases of the disease by oral administration of Chinese medicines and retention-enema, with satisfactory results reported as follows.

Therapeutic Effect of Oral Administration and External Therapy of Traditional Chinese Medicine on Cervical Tuberculous Lymphadenopathy

Objective:To analyze the clinical effect and value of oral administration and external therapy of traditional Chinese medicine for treatment of cervical tuberculous lymphadenopathy.Methods:A total of 56 patients with cervical tuberculous lymphadenopathy admitted to our hospital from January 1 to January 2018 were recruited.By using double-blind method,the patients were divided into control group(n=28)and experimental group(n=28).Control group comprised of patients with conventional anti-tuberculosis treatment,while the experimental group comprised of patients treated with oral administration and external therapy of traditional Chinese medicine.Total effective rate,incidence of complication and level of T lymphocyte subsets were compared between the two groups of cervical tuberculous lymphadenopathy patients.Results:Post-treatment data of total effective rate,complication rate,CD3+,CD4+,CD8+,CD4+/CD8+of the experimental group were compared with the control group.P<0.05;statistical analysis showed statistical significance.Post-treatment data of CD3+,CD4+,CD8+,CD4+/CD8+of both control and experimental groups were compared with pre-treatment data.P<0.05;statistical analysis showed statistical significance.Conclusion:Oral administration and external therapy of traditional Chinese medicine possesses significant effect in treatment of cervical tuberculous lymphadenopathy.

Network-meta analysis of 9 kinds of patent Chinese medicine for nourishing qi and activating blood in the treatment of angina pectoris of coronary heart disease

Objective:To evaluate the efficacy and safety of Yiqi Huoxue oral Chinese patent medicine in the treatment of angina pectoris.Methods:the databases of EMBASE,PubMed,CNKI,Wanfang and VIP were searched by computer,and the randomized controlled trial(RCT)of Yiqi Huoxue Chinese patent medicine in the treatment of angina pectoris of coronary heart disease(CHD)was searched until December 2019.By using stata15.1 software,the total clinical effective rate,the improvement rate of ECG,the improvement rate of angina pectoris,the attack frequency and duration of angina pectoris were taken as the outcome indicators for network meta analysis and mapping.Results:51 RCTs were included,including 9 kinds of traditional Chinese medicine.The results of network meta analysis showed that:in terms of clinical total effective rate,the order was Shexiang Baoxin Pill(78.2%)>xueshuanxinming tablet>Dengzhan Shengmai capsule>Shengui Capsule>Tongxinluo capsule>Tongmai Yangxin pill>Yangxin tablet>Shexiang Tongxin drop pill>Naoxintong capsule;the improvement of ECG was Tongmai Yangxin pill(85.2%)>Yangxin tablet>Dengzhan Shengmai capsule>Shexiang Tongxin drop pill>Shexiang Baoxin Pill>Tongxinluo gum Capsule>Shengui Capsule>Naoxintong capsule;in order to reduce the frequency and duration of angina pectoris,they are conventional Naoxintong capsule(88.6%)>Shengui Capsule>Tongmai Yangxin pill>Shexiang Baoxin Pill>xueshuanxinmingpian>Tongxinluo capsule>Shexiang Tongxin drop pill>Dengzhan Shengmai capsule;Shexiang Baoxin Pill(66.9%)>Dengzhan Shengmai capsule>Shexiang Tongxin drop pill>Tongxinluo capsule>xueshuanxinmingning capsule Tablet>Tongmai Yangxin pill.Conclusion:Traditional Chinese medicine combined with western medicine has obvious advantages in the treatment of angina pectoris.Shexiang Baoxin Pill,Dengzhan Shengmai capsule and Tongmai Yangxin pill can be given priority.

Systematic Review and Meta-analysis on the Efficacy and Safety of Xuefu Zhuyu Oral Liquid(血府逐瘀口服液)in the Treatment of Migraine

Objective:To systematically evaluate the efficacy and safety of Xuefu Zhuyu Oral Liquid(血府逐瘀口服液)in the treatment of migraine.Methods:All randomized controlled trials(RCTs)on the treatment of migraine with Xuefu Zhuyu Oral Liquid were screened out by systematically searching Cochrane Library,Pub Med,Embase,Web of Science,VIP,Wanfang,CNKI and CBM database from database establishment to March 2023.Literature screening was conducted strictly according to inclusion and exclusion criteria,and the quality of the finally included RCTs was evaluated according to the Cochrane Handbook.All data analyses were completed using Rev Man 5.4 software provided by the Cochrane Collaboration.Results:A total of 8 RCTs involving 706 patients were included.Meta-analysis showed that Xuefu Zhuyu Oral Liquid alone(RR=1.22,95%CI[1.11,1.33],P<0.0001)or combined with conventional treatment(RR=1.19,95%CI[1.11,1.28],P<0.0001)was superior to conventional treatment alone in improving the severity of headache attacks and reducing recurrence.Three studies mentioned mild adverse reactions in individual patients during the treatment process,such as transient diarrhea,lethargy,etc.,which were not directly related to Xuefu Zhuyu Oral Liquid.Conclusion:Based on the existing data and meta-analysis results,Xuefu Zhuyu Oral Liquid alone or combined with conventional treatment can improve the total effective rate of migraine treatment,alleviate headache symptoms,reduce recurrence and adverse events.In the future,large-scale and high-quality original studies are needed to further verify the efficacy and safety of Xuefu Zhuyu Oral Liquid in the treatment of migraine,and provide a reference for the clinical medication of migraine.

A meta-analysis of the efficacy of traditional Chinese medicine alone in the treatment of refractory gastroesophageal reflux disease

Background:To systematically evaluate the efficacy and safety of traditional Chinese medicine in the treatment of refractory gastroesophageal reflux.Methods:PubMed,The Cochrane Library,Embase,Web of Science,China National Knowledge Infrastructure,Wanfang Database,China Science and Technology Journal Database and Chinese BioMedical Literature Database were searched for randomized controlled trials of traditional Chinese medicine in the treatment of refractory gastroesophageal reflux from database establishment time to December 2020.After two researchers independently screened the literature,extracted data and evaluated the bias risk included in the study,RevMan5.3 software was used for meta-analysis.Results:A total of 12 randomized controlled trials,were included,including 893 patients.The results of meta-analysis showed that the total effective rate of the treatment group(relative risk=1.28,95%confidence interval(CI)(1.19,1.38),P<0.00001),RGERDQ(refractory gastroesophageal reflux disease)score(mean difference(MD)=−3.35,95%CI(−4.13,−2.57),P<0.00001],acid reflux(acid in the stomach comes out of the mouth)[MD=−0.30,95%CI(−0.45,−0.15),P<0.00001],heartburn(the feeling that the heart is burned)(MD=−0.44,95%CI(−0.60,−0.29),P<0.00001,and retrosternal pain(MD=−0.27,95%CI(−0.44,−0.10),P<0.00001,belching(MD=−0.40,95%CI(−0.57,−0.24),P<0.00001],endoscopic mucosal score(MD=−0.62,95%CI(−0.78,−0.46),P<0.00001],the differences were statistically significant,and the effective rate of mucosal improvement under endoscopy was P=0.93>0.05,with no statistically significant difference.Conclusion:The current evidence shows that traditional Chinese medicine in the treatment of refractory gastroesophageal reflux disease is better than that of western medicine in the total effective rate,relieving acid reflux,heartburn,retrosternal pain and belching symptoms,but it is impossible to judge the improvement of mucosa under endoscope.Due to the limitations of the quality and quantity of included studies,more high-quality studies are needed to confirm the above conclusions.

脑血疏口服液治疗中风临床应用专家共识

脑血疏口服液具有益气、活血、化瘀的功效,临床上广泛用于气虚血瘀所致中风的治疗。经多年临床观察,其对出血性中风、缺血性中风等有明显疗效,受到多个指南、共识及丛书的推荐。在总结临床医生应用经验的基础上,结合现有循证证据,遵照《中华中医药学会中成药临床应用专家共识报告规范》等,在问卷调查和文献系统回顾的基础上,基于现有最佳证据,充分结合专家经验,遵循“循证为主,共识为辅,经验为鉴”的原则,通过名义组法共达成16条推荐意见/共识建议,提出了脑血疏口服液治疗中风的用药时机、临床疗效、用法用量、疗程等,并说明了临床应用的安全性。该共识适用于各级医疗机构的医师在使用脑血疏口服液时作为用药参考。旨在提高脑血疏口服液治疗中风的临床疗效,促进合理用药,减少用药风险。共识已通过中华中医药学会的审核,并进行了发布,编号GS/CACM 331-2023。

四磨汤口服液治疗功能性消化不良临床综合评价

目的以药品临床价值为导向,对四磨汤口服液治疗功能性消化不良开展临床综合评价,为四磨汤口服液的合理定价、合理用药以及药品目录遴选提供科学依据。方法基于当前可获得数据以及调研数据,围绕四磨汤口服液与两种对照药治疗功能性消化不良的有效性、安全性、经济性、创新性、适宜性和可及性6个维度开展临床综合评价。结果有效性方面,四磨汤口服液可提高临床有效率,药理作用机制明确。安全性方面,未见毒性反应,不良反应较轻,预后良好。经济性方面,日均费用略高于对照药,具有一定成本效果优势。创新性方面,获中国专利授权,并作为中药创新药上市。适宜性方面,方便服用,在药物技术特性和药品使用方面都具有较好的适宜性。可及性方面,医院覆盖较广,产能充足,患者负担较低,长期应用无较大环境风险。3种中成药的综合价值分数从高到低依次为四磨汤口服液(92.01分)>对照药A(85.11分)>对照药B(77.51分)。专家组推荐意见为A类(21/23),建议可直接转化为决策使用。结论四磨汤口服液治疗功能性消化不良的临床综合价值较高,可为药品合理定价、合理用药以及药品目录遴选提供参考依据。

托里透毒汤口服联合紫草纱条引流促进肛周脓肿术后创面愈合的研究

目的探讨托里透毒汤方口服联合紫草纱条创面引流促进肛周脓肿患者术后创面愈合和影响炎性因子表达研究。方法选取医院2019年6月—2022年1月收治的174例肛周脓肿术的患者为研究对象,随机分为观察组(58例)、对照组A(58例)和对照组B(58例),术后所有患者给予常规处理,对照组A增加紫草纱条创面引流治疗,对照组B增加凡士林纱条创面引流治疗,观察组增加托里透毒汤方口服与紫草纱条创面引流联合治疗。比较3组患者术后第1、7、14天时疼痛程度、创面症状评分、创面愈合情况、炎性因子水平及治疗效果。结果术后第7、14天观察组血清P物质(Substance P,SP)、五羟色胺(5-Hydroxytryptamine,5-HT)水平均低于对照组A与对照组B(P<0.05),对照组A第7、14天各水平均低于对照组B(P<0.05);术后第7、14天观察组分泌物评分、水肿评分均低于对照组A与对照组B(P<0.05),对照组A7 d、14 d各评分均低于对照组B(P<0.05);观察组第7、14天创面缩小率高于对照组A与对照组B(P<0.05),对照组A第7、14天缩小率均高于对照组B,治疗后观察组创面腐肉全部脱落时间与创面愈合时间均短于对照组A与对照组B(P<0.05),对照组A各时间均低于对照组B(P<0.05);术后第7、14天观察组血清肿瘤坏死因子-α(Tumor Necrosis Factor-α,TNF-α)、C反应蛋白(C-reactive Protein,CRP)及白细胞介素-6(Interleukin-6,IL-6)炎性因子水平均低于对照组A与对照组B(P<0.05),对照组A第7天、14天各水平均低于对照组B(P<0.05);治疗后观察组患者总有效58例(100.00%)显著比对照组A患者54例(93.10%)和对照组B患者50例(86.21%)高(P<0.05),对照组A总有效率比对照组B高,但两组比较差异不存在统计学意义(P>0.05)。结论托里透毒汤口服联合紫草纱条创面引流可以促进术后创面愈合,降低炎性因子水平,缩短康复进程,值得推广。

基于中医传承辅助平台的中药内服治疗原发性骨质疏松症组方用药规律研究

目的:基于数据挖掘方法探讨中医药治疗原发性骨质疏松症的组方用药规律。方法:检索中国知网、维普、万方等中文数据库2006—2022年中药内服治疗原发性骨质疏松症的中药方剂,通过中医传承辅助平台系统软件(TCMISS)运用关联规则算法、复杂系统熵聚类方法,统计处方中药物的性味归经、使用频率、药物之间的关联规则、核心药物组合和高频中药组合。结果:纳入文献共计210篇,涉及224首方剂,168味中药。总结高频证候分型,居于前4位的分别是肾虚血瘀证、脾肾亏虚证、肝肾阴虚证、肾虚证。性味归经最多为温性药,五味频次最多为甘味药。药物归经前4位的是肝、肾、脾及心经。单味中药使用频次居于前10位的是熟地黄、淫羊藿、当归、杜仲、黄芪、骨碎补、补骨脂、山茱萸、山药、枸杞子。关联规则分析得到45个药对组合及44条关联规则。聚类分析得到20个药物核心组合,优化出10个新方组合。结论:原发性骨质疏松症病因以肾、脾亏虚为主,兼有血瘀,中医药治疗以补益肝肾、健脾益气、活血补血为主。

三级综合性医院门诊中成药处方点评及使用现状分析

目的 分析三级综合性医院门诊中成药处方使用现状。方法 依据《医院处方点评管理规范(试行)》、药品说明书和《中成药临床应用指导原则》等,对湘雅常德医院2020年5—12月门诊处方中的中成药处方进行随机抽查点评并对其结果进行归纳分析,采取行政干预4个月后再次抽查2021年5—12月中成药处方并归纳分析。结果 行政干预后中成药不合理处方占比为10.98%,低于行政干预前的21.87%(χ^(2)=152.364,P<0.001)。行政干预后,耳鼻喉科、神经内科、泌尿外科、骨科及儿科急诊中成药处方不合理占比降低较为显著(P<0.05);重复用药的问题较前明显改善,而临床诊断相关问题则成为中成药处方最典型的问题;儿童中成药不合理处方占比为8.72%,低于干预前的18.36%(χ^(2)=11.911,P=0.001)。结论 三级综合性医院门诊在中成药使用上仍存在一定问题,行政措施干预后可以解决一部分问题,但临床医师需加强中医药辨证施治方面的知识学习,中成药处方点评制度与规范需进一步完善,以期促进中成药的合理使用。

癌痛中医治疗方案及效果的研究进展

癌性疼痛(简称癌痛)已经成为癌症患者最为常见的并发症之一,在造成癌症患者疼痛症状的同时亦会对生活质量造成严重损伤。三阶梯镇痛方案在癌痛患者中的应用既有其风险所在,亦有一定的局限性。而中医治疗方案的使用对提升患者镇痛效果有积极作用,其中常见方案如内服外治、针灸艾灸、中成药物等在癌痛患者的治疗中已得到广泛应用,取得显著效果。但中医治疗方案在癌痛患者中的应用必须建立在对癌痛本身病理机制的深入认知上,如此才能确保中医方案在癌痛治疗中的应用安全性和有效性。文章针对癌痛中医方案和实施效果进行简单综述。

中医治疗紧张性头痛的研究进展

紧张性头痛(TTH)又称肌收缩性头痛,属于功能性头痛中最常见的类型之一,其表现为紧束性或压迫性非搏动性头痛,可伴或不伴有头部肌群的挛缩性收缩及压痛,呈发作性或持续性,病程数日至数年不等。随着生活节奏的加快,社会压力的增大,其发病率呈逐渐上升的趋势,好发育中青年,女性略高于男性。中医学将其归于“头痛”“首风”“头风”等范畴,虽然在发病中有多种致病因素在起作用,但是中医学通过四诊合参进行辨证论治,针对每个患者病因病机不同处以方药、针灸、推拿、按摩等中医外治,近年来各项研究数据显示,中医内服用药及外治疗法所达到的成效不容小觑,随着中医学的现代化发展,现代医家汲取古代医家宝贵经验,去粗取精,对于紧张性头痛不断深入研究,在传统治疗的基础上加上现代化仪器等,在治疗方面涌现出了更多的诊治方法,且其临床疗效满意。文章归纳近10年关于中医治疗紧张性头痛的文献,归纳中医治疗方法,以探讨更有效的治疗方案,提高临床疗效。

中药内服法治疗糖尿病视网膜病变研究概况

糖尿病是危害人类生命与健康安全的三大疾病之一,除了疾病本身给患者生活造成不便外,随着病情的进展,其产生的多种并发症对患者的影响也不容小觑。视网膜病变是常见的糖尿病并发症之一,严重影响患者的身心健康。中药内服法治疗糖尿病性视网膜病变具有疗效较好、不良反应小等优势。因此,该文对近些年来医家们对糖尿病视网膜病变病因病机的认识及中药方剂内服法医治糖尿病视网膜病变的疗效和作用机制的相关研究进行综述,为临床使用中药治疗糖尿病视网膜病变提供依据与参考。

中药内服及外洗联合血液灌流治疗维持性血液透析伴皮肤瘙痒患者的效果研究

目的:研究中药内服及外洗联合血液灌流治疗维持性血液透析伴皮肤瘙痒患者的效果。方法:选择2022年7月—2023年7月萍乡矿业集团有限责任公司总医院收治的80例维持性血液透析伴皮肤瘙痒患者为研究对象,按随机数字表法分为治疗组和对照组,各组40例。两组均接受血液透析联合血液灌流治疗,对照组接受皮肤瘙痒非药物治疗,治疗组在对照组基础上接受中药内服及经验方祛风止痒安神汤外洗治疗,两组治疗时间均为4周。比较两组实验室指标、瘙痒情况、睡眠质量、生活质量、不良反应。结果:治疗4周后,治疗组组胺(HIS)、甲状旁腺激素(PTH)、血尿素氮(BUN)、血肌酐(Scr)、β_(2)-微球蛋白(β_(2)-MG)均明显低于对照组,血钙、血磷达标率均明显高于对照组,差异均有统计学意义(P<0.05)。治疗4周后,治疗组瘙痒评分、阿森斯失眠量表(AIS)评分均明显低于对照组,治疗组世界卫生组织生存质量测定量表(WHOQOL-BREF)各维度评分及总分均高于对照组,差异均有统计学意义(P<0.05)。治疗期间两组均未出现严重不良反应。结论:中药内服及外洗联合血液灌流治疗维持性血液透析伴皮肤瘙痒患者的效果明显,有助于维持钙磷代谢平衡,对改善皮肤瘙痒及睡眠质量有积极作用,可提高患者生活质量。

灸八髎穴联合内服益气润肠中药汤剂治疗1例中风后气虚便秘患者的护理体会

本文总结灸八髎穴联合内服益气润肠中药汤剂治疗1例中风后气虚便秘患者的护理体会。在完善护理评估的基础上,遵医嘱给予八髎穴艾灸、针灸等中医外治疗法,以增强肠道蠕动,缓解便秘;给予益气润肠中药汤剂内服,从根本上调理;同时基于子午流注理论,为患者开具饮水处方,以软化粪便,促进胃肠蠕动,利于排便;结合患者的疾病特点予以饮食调护、运动疗法和情志护理。经过10d中医内服外用联合治疗以及辨证施护,患者气虚便秘症状得到有效改善。

从中成药产业链试论品质提升

中成药制造作为21世纪最具发展潜力的产业,已被提升到国家战略的高度。中成药要立足于市场,促进中医的发展,得到消费者的信任,归根结底还是要靠品质。本文立足于中成药产业链的发展全局,针对中成药品质提升关键环节中的要点和方法进行了探讨,提出只有从源头上保证中药材质量,加强药材前处理的过程控制,全力提升制药工业的自动化、数字化、智能化水平,让质量监管成为常态化,才能保证产品质量,进一步促进中药产业的高质量发展。

基于数据挖掘技术探讨中药治疗急性附睾炎用药规律

目的:基于数据挖掘技术探讨中药治疗急性附睾炎的用药规律。方法:检索中国知网(CNKI)、万方数据知识服务平台(WF)自建库至2023年8月1日公开发表的中药治疗急性附睾炎的相关文献。分别建立内服、外用中药处方数据库,运用中医传承辅助平台V3.5软件统计药物使用频次、功效、四气、五味、归经,以及进行关联规则和聚类分析。结果:筛选后获取文献95篇,其中内服中药文献74篇,外用中药文献21篇。得到102首处方,包括63首内服中药处方和39首外用中药处方。内服中药使用频次排名前5的是甘草、当归、柴胡、泽泻、龙胆草,外用中药使用频次排名前5的是大黄、黄柏、天花粉、甘草、白芷。内服中药功效多见清热、活血化瘀、利水渗湿,外用中药功效多见清热、活血化瘀、泻下。内服、外用中药四气皆以寒性为主,其次为温性;五味皆以苦味为主,其次为甘味或辛味。内服中药排名前3的归经是肝、肺、心经,外用中药排名前3的归经是脾、肝、肺经。通过关联规则分析,内服中药获得30条常用药物组合、8条核心药物关联规则;外用中药获得6条常用药物组合、7条核心药物关联规则。通过聚类分析,内服中药获得4个核心药物组合,外用中药获得3个核心药物组合。结论:中药治疗急性附睾炎无论内服还是外用,都强调清热解毒、活血化瘀,组方皆以苦寒清热药为主。内服中药核心药物组合针对急性附睾炎早期湿热蕴结、热毒壅盛和后期瘀血阻络、瘀毒互结之病机,分别治以清热利湿、活血解毒和活血化瘀、清热解毒、软坚散结之法。外用中药核心药物组合则常以清热利湿药、清热解毒药配以活血化瘀药,以改善局部症状为主。